Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American ConferenceAlan Huber, J.K. Everett, Ahmet Özen et al.|Journal of Clinical Immunology|2021Cited by 28
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M. Ellerbroek, Leman Yel, Leif G. Hanitsch et al.|Immunotherapy|2024Cited by 5
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy AdultsAndrás Nagy, Zhaoyang Li, Kimberly Duff et al.|Journal of Clinical Immunology|2023Cited by 3
Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USAArye Rubinstein, Leman Yel, Mohsen Mabudian et al.|Clinical Immunology|2023Cited by 1
Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participantsZhaoyang Li, Leman Yel, András Nagy et al.|Clinical Immunology|2023Cited by 1